指南与共识临床生化临床免疫质量管理与危急值

应对娱乐性一氧化二氮使用的隐性流行:EFL M生物标志物委员会立场与建议

Addressing the silent epidemic of recreational nitrous oxide use: a position, call to action and recommendations by the European Federation of Clinical Chemistry and Laboratory Medicine Committee on Biological Markers of Nitrous Oxide Abuse.
指南 / 共识 · Clin Chem Lab Med · 2025-11-20

该立场文件由欧洲临床化学与检验医学联合会(EFLM)一氧化二氮滥用生物标志物委员会制定,指出娱乐性一氧化二氮使用正成为公共卫生问题,伴随神经、精神及血栓并发症报告增多。文件提出短期建议聚焦早期临床识别、及时生物检测和结构化患者管理,并明确血浆同型半胱氨酸(HCY)和甲基丙二酸(MMA)在诊断中的核心地位。长期目标包括生物标志物检测标准化、国际患者登记和跨学科专家网络建设。

要点

  • 年轻个体出现不明原因感觉异常、步态不稳、膀胱肠道症状、性功能障碍、情绪障碍或血栓栓塞时需警惕一氧化二氮滥用。
  • 血浆HCY是近期暴露的敏感标志物,MMA指示临床严重程度,维生素B12和叶酸检测也必不可少。
  • 因生物标志物快速正常化,应在入院时检测,并立即开始维生素B12补充,同时注意标志物动力学和患者自我补充可能。

核心结论

  • 娱乐性一氧化二氮使用是日益增长的公共卫生问题,需临床和实验室提高认识并协调行动。
  • 短期建议聚焦早期临床识别、及时生物检测和结构化患者管理,长期目标包括检测标准化、国际登记和专家网络建设。

研究设计与样本

  • 欧洲临床化学与检验医学联合会(EFLM)一氧化二氮滥用生物标志物委员会发布的立场文件、行动呼吁和建议。

主要发现

  • 娱乐性一氧化二氮使用伴随神经、精神及血栓并发症报告增多。
  • 关键临床症状包括年轻个体不明原因感觉异常、步态不稳、膀胱肠道症状、性功能障碍、情绪障碍和血栓栓塞事件。
  • 血浆HCY是近期暴露的敏感标志物,MMA指示临床严重程度。
  • 维生素B12水平可能假性安心(常处于正常低值),维生素B12和叶酸检测也必不可少。
  • 生物标志物快速正常化,检测应在入院时进行,维生素B12补充应立即开始。

关键数值与推荐

  • 血浆同型半胱氨酸(HCY)作为近期暴露的敏感标志物,血浆甲基丙二酸(MMA)指示临床严重程度。
  • 维生素B12和叶酸测量必不可少,但B12水平可能假性安心(常处于正常低值)。
  • 因生物标志物快速正常化,检测应在入院时进行,维生素B12补充应立即开始,需注意标志物动力学和患者自我补充可能。

临床怎么用

  • 对年轻个体出现不明原因感觉异常、步态不稳、膀胱肠道症状、性功能障碍、情绪障碍或血栓栓塞事件时,应怀疑娱乐性一氧化二氮使用。
  • 入院时即检测血浆HCY、MMA、维生素B12和叶酸,并立即开始维生素B12补充。
  • 注意生物标志物快速正常化及患者自我补充对检测结果的潜在影响。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Recreational nitrous oxide (N2O) use has emerged as a growing public health concern, with increasing reports of neurological, psychiatric, and thrombotic complications. This position paper from the EFLM Committee on Biological Markers of Nitrous Oxide Abuse highlights the urgent need for clinical and laboratory awareness, alongside coordinated action from healthcare systems and the scientific community. Short-term recommendations focus on early clinical recognition, prompt biological testing, and structured patient management. Key clinical symptoms include unexplained sensory disturbances, gait instability, bladder and bowel complaints, sexual dysfunction, mood disorders, and thromboembolic events in young individuals. Plasma homocysteine (HCY) and plasma methylmalonic acid (MMA) are central to the diagnostic approach, with HCY serving as a sensitive marker of recent exposure and MMA indicating clinical severity. Vitamin B12 and folate measurements are also essential, though B12 levels may be falsely reassuring (often in the low-normal range). Given the rapid normalization of biomarkers, testing should be performed on admission, and vitamin B12 supplementation should begin without delay, with caution regarding biomarker kinetics and possible self-supplementation by patients. In addition, this paper outlines long-term goals, including the harmonization of biomarker assays, creation of international patient registries, and development of interdisciplinary expert networks. Notably, the international network PROTOSIDE (www.protoside.com) plays a key role in facilitating case discussion, expert collaboration, and dissemination of best practices in the management of N2O-related complications. A continuous bibliographic watch and support for translational research are necessary to improve biomarker discovery and understanding of the underlying mechanisms of toxicity. By combining immediate clinical action with long-term scientific and policy development, this document lays the foundation for an international strategy to address the silent but expanding epidemic of nitrous oxide misuse.

来源:Clin Chem Lab Med,查看原文。版权归原作者所有。

引用

  1. Grzych G, Lee GR, Alpdemir M, et al. Addressing the silent epidemic of recreational nitrous oxide use: a position, call to action and recommendations by the European Federation of Clinical Chemistry and Laboratory Medicine Committee on Biological Markers of Nitrous Oxide Abuse. Clin Chem Lab Med. 2025. PMID: 41292176. doi:10.1515/cclm-2025-1060

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。